Related Experiment Video
Updated: Jun 16, 2026
Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers
Published on: December 5, 2017
Multichromatic phenotyping of HER receptor coexpression in breast tumor tissue samples using flow
Arabel Vollmann-Zwerenz1, Simone Diermeier-Daucher, Anja Kathrin Wege
1Institute of Pathology, University of Regensburg, Germany.
Abstract:
The prognostic significance of HER2 expression in human breast carcinomas is beyond dispute nowadays. The HER family of receptor tyrosine kinases comprises four members (HER1/ErbB1/EGFR, HER2/ErbB2, HER3/ErbB3, and HER4/ErbB4) that act in concert via transactivation and consequently compose a functional signaling unit. Besides HER2 overexpression, coexpression of other HER receptors has substantial impact on course of disease and potential therapeutic benefit. This observation is substantiated by numerous preclinical studies and retrospective studies done on patients with breast cancer. Against this background, the quantification of all HER receptor expressions at the same time would significantly extend the information content revealed by routine diagnosis of breast cancer tissues. Moreover, the knowledge of HER receptor coexpression profiles in primary tumor samples could provide the basis to design and develop highly specific antireceptor treatment strategies. Here, we report on a simultaneous flow cytometric detection of all four HER receptors on carcinoma cells isolated from primary breast cancer tissues and separated from nonepithelial cells by cytokeratin staining. Combined with DNA, i.e. ploidy quantification, the approach resulted in a six-parameter assay that could complement the diagnosis of a variety of diseases in which HER receptor expression has a pivotal impact on the degree of malignancy.
Insights
This study developed a novel assay for simultaneously detecting all four human epidermal growth factor receptor (HER) family members in breast cancer cells. This method enhances diagnostic information and aids in developing targeted therapies for improved patient outcomes.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- The prognostic significance of Human Epidermal growth factor Receptor 2 (HER2) in breast cancer is well-established.
- The HER family (HER1-HER4) functions as a signaling unit, and coexpression of its members impacts disease progression and therapeutic response.
- Current diagnostics primarily focus on HER2, potentially missing crucial information from other HER receptors.
Purpose of the Study:
- To develop a simultaneous detection method for all four HER receptors (HER1-HER4) in primary breast cancer tissues.
- To establish a comprehensive HER receptor coexpression profiling for enhanced diagnostic and therapeutic insights.
- To integrate this profiling with DNA ploidy quantification for a multi-parameter diagnostic assay.
Main Methods:
- Isolation of carcinoma cells from primary breast cancer tissues using cytokeratin staining to exclude non-epithelial cells.
- Simultaneous flow cytometric detection of all four HER receptors (HER1/ErbB1/EGFR, HER2/ErbB2, HER3/ErbB3, and HER4/ErbB4).
- Integration of DNA ploidy quantification to create a six-parameter assay.
Main Results:
- Successful simultaneous detection of all four HER receptors on isolated carcinoma cells.
- Demonstration of a six-parameter assay combining HER receptor expression and DNA ploidy.
- Validation of the assay's potential to provide extended diagnostic information beyond routine HER2 assessment.
Conclusions:
- Simultaneous HER receptor quantification offers a more comprehensive understanding of breast cancer biology.
- This multi-parameter assay can significantly enhance the diagnostic information available for breast cancer.
- The developed method provides a foundation for designing highly specific anti-receptor treatment strategies tailored to individual patient profiles.
